Legal & General Group Plc raised its position in ABIOMED, Inc. (NASDAQ:ABMD) by 13.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 36,315 shares of the medical equipment provider’s stock after purchasing an additional 4,416 shares during the period. Legal & General Group Plc owned 0.08% of ABIOMED worth $6,123,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Lord Abbett & CO. LLC increased its stake in shares of ABIOMED by 282.5% in the 2nd quarter. Lord Abbett & CO. LLC now owns 60,882 shares of the medical equipment provider’s stock valued at $8,724,000 after acquiring an additional 44,967 shares in the last quarter. Eagle Asset Management Inc. increased its stake in shares of ABIOMED by 16.2% in the 2nd quarter. Eagle Asset Management Inc. now owns 227,467 shares of the medical equipment provider’s stock valued at $32,596,000 after acquiring an additional 31,690 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of ABIOMED by 21.7% in the 2nd quarter. Victory Capital Management Inc. now owns 9,761 shares of the medical equipment provider’s stock valued at $1,399,000 after acquiring an additional 1,738 shares in the last quarter. State of Tennessee Treasury Department bought a new stake in shares of ABIOMED in the 3rd quarter valued at $5,058,000. Finally, BNP Paribas Arbitrage SA increased its stake in shares of ABIOMED by 45.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 16,206 shares of the medical equipment provider’s stock valued at $2,322,000 after acquiring an additional 5,055 shares in the last quarter. Hedge funds and other institutional investors own 90.92% of the company’s stock.

Shares of ABIOMED, Inc. (ABMD) opened at $188.71 on Friday. The company has a market cap of $8,344.00, a price-to-earnings ratio of 120.97, a price-to-earnings-growth ratio of 2.51 and a beta of 0.15. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.20 and a current ratio of 5.84. ABIOMED, Inc. has a one year low of $103.53 and a one year high of $200.28.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 EPS for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.16. The business had revenue of $132.80 million during the quarter, compared to analyst estimates of $131.18 million. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. ABIOMED’s quarterly revenue was up 28.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.20 EPS. equities research analysts forecast that ABIOMED, Inc. will post 2.38 earnings per share for the current fiscal year.

ABMD has been the subject of several research analyst reports. BidaskClub lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Saturday, August 26th. Jefferies Group reiterated a “buy” rating and issued a $175.00 price objective on shares of ABIOMED in a research note on Tuesday, August 29th. Piper Jaffray Companies reiterated a “buy” rating and issued a $160.00 price objective on shares of ABIOMED in a research note on Tuesday, August 29th. SunTrust Banks initiated coverage on shares of ABIOMED in a research note on Friday, September 29th. They issued a “buy” rating and a $195.00 price objective for the company. Finally, Zacks Investment Research lowered shares of ABIOMED from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $190.43.

In other ABIOMED news, Director Dorothy E. Puhy sold 6,364 shares of the business’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the completion of the sale, the director now owns 39,532 shares in the company, valued at approximately $7,079,390.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Andrew J. Greenfield sold 11,282 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $169.32, for a total transaction of $1,910,268.24. The disclosure for this sale can be found here. Insiders have sold a total of 27,646 shares of company stock valued at $4,836,333 in the last 90 days. 7.00% of the stock is currently owned by company insiders.

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/abiomed-inc-abmd-stake-lifted-by-legal-general-group-plc/1769116.html.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.